Antiviral infusion composition
An antiviral transfusion composition using a specific sugar mixture effectively inhibits viral infections and boosts immunity by combining glucose, galactose, mannose, fucose, xylose, N-acetylglucosamine, N-acetylgalactosamine, and N-acetylneuraminic acid, addressing the limitations of existing treatments and demonstrating substantial antiviral efficacy.
Patent Information
- Application Number
- PCT/KR2023/006231
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-08
- Publication Date
- 2024-11-14
AI Technical Summary
Current antiviral treatments are insufficient in effectively addressing a wide range of viral infections, including retroviruses, lentiviruses, and adenoviruses, and do not adequately enhance immunity against viral diseases.
An antiviral transfusion composition containing a specific combination of sugars, including glucose, galactose, mannose, fucose, xylose, N-acetylglucosamine, N-acetylgalactosamine, and N-acetylneuraminic acid, which can be administered via infusion, potentially combined with amino acids, to exhibit antiviral activity and enhance immunity.
The composition demonstrates significant antiviral effects, inhibiting retrovirus, lentivirus, and adenovirus infections by over 80%, 17%, and 11% respectively, and enhances interferon production for improved viral immunity.
Smart Images

Figure KR2023006231_14112024_PF_FP_ABST
Abstract
Description
Antiviral fluid composition
[0001] The present invention relates to an antiviral sap composition.
[0002] Key substances studied in the field of life sciences include proteins, amino acids, nucleic acids, fats, fatty acids, carbohydrates, polysaccharides, and sugars. Life science and medical researchers have long recognized proteins as the primary communication molecules within the body. However, they have concluded that proteins alone are insufficient for transmitting all messages within cells. Consequently, they have begun studying glycoproteins, which are combinations of protein and carbohydrate molecules.
[0003] Eight types of sugars, including glucose (Glu), galactose (Gal), mannose (Man), L-fucose (Fuc), xylose (Xy), N-acetylglucosamine (GlcNAc), N-acetylgalactosamine (GalNAc), and N-acetylneuraminic acid (NANA; or sialic acid), play a very important role in maintaining physiological activity in the body.
[0004] The present inventors confirmed that a sap composition containing the above eight types of sugars has an antiviral effect, and completed the present invention.
[0005] The present invention provides an antiviral aqueous solution composition containing a specific sugar.
[0006] To solve the above problem, the present invention discloses an antiviral sap composition containing a specific sugar.
[0007] Specifically, the aqueous solution composition of the present invention includes sugars such as glucose, galactose, mannose, fucose, xylose, N-acetylglucosamine, N-acetylgalactosamine, and N-acetylneuraminic acid.
[0008] The aqueous composition of the present invention has antiviral activity, particularly against retroviruses, lentiviruses, adenoviruses, etc.
[0009] The sap composition of the present invention can treat, alleviate or prevent diseases caused by viruses (e.g., acquired immunodeficiency syndrome, respiratory infection, digestive infection, otitis media, pharyngitis, laryngitis, keratitis, conjunctivitis, influenza, cold, skin infection, genital infection, hepatitis, etc.).
[0010] In addition, the present invention relates to a composition for enhancing immunity against viruses, comprising glucose, galactose, mannose, fucose, xylose, N-acetylglucosamine, N-acetylgalactosamine and N-acetylneuraminic acid.
[0011] The aqueous solution composition of the present invention may further comprise one or more amino acids.
[0012] Here, the amino acid may be selected from at least one of 20 amino acids that can constitute proteins of the human body, and for example, at least one may be selected from the group consisting of isoleucine, leucine, lysine acetate, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, aspartic acid, cysteine, glutamic acid, histidine, proline, serine, tyrosine, and glycine.
[0013] The sap composition according to the present invention can be administered by infusion into a vein of the human body.
[0014] In addition, the present invention relates to a method for treating a disease caused by a virus or enhancing immunity against a virus by administering to a human a sap composition as described above.
[0015] The sap composition according to the present invention exhibits excellent antiviral effects.
[0016] Figure 1 illustrates the results of an antiviral experiment of the composition of the present invention against a retrovirus.
[0017] Figure 2 illustrates the results of an antiviral experiment of the composition of the present invention against lentivirus.
[0018] Figure 3 illustrates the results of an antiviral experiment of the composition of the present invention against adenovirus.
[0019] Figure 4 illustrates the results of an experiment on the interferon expression effect by the composition of the present invention.
[0020] The present invention will be described in detail with reference to the following examples. However, the following examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention.
[0021] Example 1: Preparation of sugar-containing aqueous solution
[0022] Eight sugars, including glucose, galactose, mannose, fucose, xylose, N-acetylglucosamine, N-acetylgalactosamine, and N-acetylneuraminic acid, obtained from Sigma-Aldrich (St. Louis, MO, USA), were dissolved in water for injection (Jungwoo Pharmaceutical). Aspartic acid (L-Aspartic acid), a type of amino acid, was used as a stabilizer.
[0023] To adjust the pH of the manufactured sugar-containing solution, a 1N NaOH solution (Samchun Pure Chemical Co.) was used. The pH was adjusted to 7.0 using a pH meter (METTLER TOLEDO Seven Compact pH / Ion).
[0024] Table 1 shows the composition of the above sugar-containing solution.
[0025] Ingredients per solution (mg) L-(-)-Fucose 3 1 D-(+)-Galactose 3 1 D-(+)-Xylose 3 1 D-(+)-Glucose 3 1 D-(+)-Mannose 3 1 N-Acetylneuraminic acid 3 1 N-Acetyl-D-galactosamine 3 1 N-Acetyl-D-glucosamine 3 1 Stabilizer (mg) Aspartic acid 2 0 Solvent Water for injection qspH Regulator (㎕) 1 N NaOH q.s. Total 10 mL
[0026] * This is a composition table based on a total of 10 mL (actually 50 mL was manufactured)
[0027] ** The content of 8 sugars in the above composition is 31 mg x 8 / 10 mL ≒ 2.5 (w / v)%.
[0028] Example 2: Experiments on retroviruses
[0029] a. Cell plating
[0030] On the first day (Day 1), HEK293T cells cultured in DMEM culture medium were seeded at 5 × 10 in 6-well plates. 5 Cells were plated in the amount of 1 / well and cultured in an incubator (37°C, CO25%) for 24 hours.
[0031] B. Sugar mixture treatment
[0032] On the second day (Day 2), the sugar-containing composition prepared in Example 1 was added to the wells of the test group. Here, the total of the eight sugars added was diluted to a concentration of 0.25 (w / v)%, 0.5 (w / v)%, and 1 (w / v)%, respectively, based on the total amount of the composition present in each well (i.e., the total amount of the entire composition including the added sugar-containing composition).
[0033] No sugar-containing composition was added to the control wells.
[0034] Afterwards, it was cultured in an incubator (37°C, CO25%) for 24 hours.
[0035] B. Viral infection
[0036] On the third day (Day 3), GFP (Green Fluorescent Protein)-tagged retrovirus or an empty vector (pMD2.G or psPAX2) that does not express the virus was added to each well and incubated for 48 hours to prepare an experimental group in which cells were infected with the virus and a control group that was not infected with the virus.
[0037] A. Check the effect
[0038] On Day 5, the culture medium in each well was removed and washed twice with PBS buffer. The cells were then detached from the wells by treatment with trypsin.
[0039] Afterwards, PBS buffer was added to each well and pipetted into e-tubes. Afterwards, centrifugation was performed at 3000 rpm for 5 minutes, the supernatant was removed, and the suspension was resuspended in FACS buffer.
[0040] Subsequently, the number of virus-infected cells was measured using GFP-derived fluorescence.
[0041] The experimental results are shown in Fig. 1. The experimental results showed that treatment with the sugar-containing composition according to the present invention inhibited infection by retrovirus in cells by more than 80%.
[0042] Example 3: Experiments on lentiviruses
[0043] a. Cell plating
[0044] On the first day (Day 1), 5 × 10 MDA-MB-231 cells cultured in DMEM culture medium were seeded in 6-well plates. 5 Cells were plated in the amount of 1 / well and cultured in an incubator (37°C, CO25%) for 24 hours.
[0045] B. Sugar mixture treatment
[0046] On the second day (Day 2), the sugar-containing composition prepared in Example 1 was added to the wells of the test group. Here, the total of the eight sugars added was diluted to a concentration of 1 (w / v)% based on the total amount of the composition present in each well (i.e., the total amount of the entire composition including the added sugar-containing composition).
[0047] No sugar-containing composition was added to the control wells.
[0048] Afterwards, it was cultured in an incubator (37°C, CO25%) for 24 hours.
[0049] B. Viral infection
[0050] On the third day (Day 3), GFP-tagged lentivirus or an empty vector that does not express the virus was added to each well and incubated for 24 hours to prepare an experimental group in which cells were infected with the virus and a control group that was not infected with the virus.
[0051] A. Check the effect
[0052] On the fourth day (Day 4), the culture medium in each well was removed and washed twice with PBS buffer. The cells were then detached from the wells by treatment with trypsin.
[0053] Afterwards, PBS buffer was added to each well and pipetted into e-tubes. Afterwards, centrifugation was performed at 3000 rpm for 5 minutes, the supernatant was removed, and the suspension was resuspended in FACS buffer.
[0054] Subsequently, the number of virus-infected cells was measured using GFP-derived fluorescence.
[0055] The experimental results are shown in Fig. 2. As a result of the experiment, when treated with the sugar-containing composition according to the present invention, it was shown to have an excellent antiviral effect against lentivirus, as infection by lentivirus in cells was inhibited by about 17%.
[0056] Example 4: Experiments on adenovirus
[0057] a. Cell plating
[0058] On the first day (Day 1), HEK 293T cells cultured in DMEM culture medium were seeded at 5 × 10 in 6-well plates. 5 Cells were plated in the amount of 1 / well and cultured in an incubator (37°C, CO25%) for 24 hours.
[0059] B. Sugar mixture treatment
[0060] On the second day (Day 2), the sugar-containing composition prepared in Example 1 was added to the wells of the test group. Here, the sum of the eight sugars added was diluted to a concentration of 1% of the total amount of the composition present in each well (i.e., the total amount of the entire composition including the added sugar-containing composition).
[0061] No sugar-containing composition was added to the control wells.
[0062] Afterwards, it was cultured in an incubator (37°C, CO25%) for 24 hours.
[0063] B. Viral infection
[0064] On the third day (Day 3), GFP-tagged adenovirus or an empty vector that does not express the virus was added to each well and incubated for 24 hours to prepare an experimental group in which cells were infected with the virus and a control group that was not infected with the virus.
[0065] A. Check the effect
[0066] On the fourth day (Day 4), the culture medium in each well was removed and washed twice with PBS buffer. The cells were then detached from the wells by treatment with trypsin.
[0067] Afterwards, PBS buffer was added to each well and pipetted into e-tubes. Afterwards, centrifugation was performed at 3000 rpm for 5 minutes, the supernatant was removed, and the suspension was resuspended in FACS buffer.
[0068] Subsequently, the number of virus-infected cells was measured using GFP-derived fluorescence.
[0069] The experimental results are shown in Fig. 3. As a result of the experiment, when treated with the sugar-containing composition according to the present invention, it was shown that the infection by adenovirus in cells was inhibited by about 11%, showing an excellent antiviral effect even against lentivirus.
[0070] Example 5: Experiment to enhance immunity against viruses
[0071] a. Cell plating
[0072] On the first day (Day 1), RAW 264.7 cells cultured in DMEM culture medium were seeded at 1 × 10 in a 24-well plate. 6 Cells were plated in the amount of 1 / well and cultured in an incubator (37°C, CO25%) for 24 hours.
[0073] B. Sugar mixture treatment
[0074] On the second day (Day 2), the sugar-containing composition prepared in Example 1 was added to the wells of the test group. Here, the sum of the eight added sugars was diluted to a concentration of 1 (w / v)% based on the total amount of the composition present in each well (i.e., the total amount of the entire composition including the added sugar-containing composition). No sugar-containing composition was added to the wells of the control group.
[0075] After 30 minutes of adding the mixture of eight sugars, the cells were treated with 200 μg / ml of Poly (I:C) and cultured in an incubator (37°C, CO25%) for 24 hours.
[0076] All. Check the effect
[0077] On the third day (Day 3), cells were collected and RNA was collected from the cells.
[0078] After RNA collection, cDNA was synthesized, real-time PCR was performed, and mRNA expressing interferon α and β was measured.
[0079] The primer information for PCR is as follows:
[0080] Interferon αFCAACACCTACACAGGTTACCRAGTGGCTTCCCAGATGTTCCInterferon βFTCCAAGAAAGGACGAACATTRTGAGGACATCTCCCACGTCA
[0081] PCR conditions are as follows:
[0082] StageStepTemperature(℃)TimeCycleHold stagestep 1502 minutes1step 29610 minutesPCR stagestep 19615 seconds40 steps 2601 minutesMelt curve stagestep 19615 seconds1step 2601 minutesStep 3(dissociation)9615 seconds
[0083] The experimental results are shown in Fig. 4. As a result of the experiment, it was confirmed that the composition according to the present invention increases the production of interferon (IFN) α, which is essential for viral immunity to fight viruses in the human body.
[0084] The sap composition of the present invention has excellent antiviral effects and immune effects against viruses.
Claims
1. An antiviral fluid composition comprising glucose, galactose, mannose, fucose, xylose, N-acetylglucosamine, N-acetylgalactosamine and N-acetylneuraminic acid.
2. A sap composition according to claim 1, characterized in that the virus is a rhetorvirus, lentivirus or adenovirus.
3. A sap composition according to claim 1 or 2, further comprising one or more amino acids.
4. A composition for enhancing immunity against viruses, comprising glucose, galactose, mannose, fucose, xylose, N-acetylglucosamine, N-acetylgalactosamine and N-acetylneuraminic acid.
5. A sap composition according to claim 1, further comprising one or more amino acids.
Citation Information
Patent Citations
Compositions for-detecting of influenza viruses and kits and methods using same
KR1020080083266A
An infusion solution comprising saccharide
KR1020180105424A
Repair kit for flow control valve of a fuel injector using heavy Diesel vehicles
KR102240085B1
Methods and compositions for dual glycan binding AAV vectors
US20160017005A1
Viral vectors with reduced immunogenicity
WO2022204504A1
